The WavelinQ™ Arterio-Venous Endovascular Fistula: A Global, Post-Market Investigation
Last updated on July 2021Recruitment
- Recruitment Status
- Recruiting
- Estimated Enrollment
- Same as current
Summary
- Conditions
- AV Fistula
- Chronic Kidney Diseases
- End Stage Kidney Disease
- Fistulas Arteriovenous
- Kidney Disease, Chronic
- Kidney Failure
- Kidney Insufficiency
- Type
- Interventional
- Phase
- Not Applicable
- Design
- Allocation: N/AIntervention Model: Single Group AssignmentMasking: None (Open Label)Primary Purpose: Treatment
Participation Requirements
- Age
- Between 18 years and 125 years
- Gender
- Both males and females
Description
The purpose of this clinical investigation is to provide clinical evidence to further demonstrate reasonable assurance of safety and effectiveness of the WavelinQ™ EndoAVF System when used for endovascular arteriovenous fistula (endoAVF) creations. Treated participants will be followed for 24-months...
The purpose of this clinical investigation is to provide clinical evidence to further demonstrate reasonable assurance of safety and effectiveness of the WavelinQ™ EndoAVF System when used for endovascular arteriovenous fistula (endoAVF) creations. Treated participants will be followed for 24-months post index procedure.
Tracking Information
- NCT #
- NCT04626427
- Collaborators
- Not Provided
- Investigators
- Principal Investigator: Charmaine Lok, MD, MSc University Health Network, Toronto Principal Investigator: Nicholas Inston, PhD The Queen Elizabeth Hospital Principal Investigator: Panagiotis Kitrou, MD, MSc, PhD University Hospital of Patras
Get Well Soon